Protective and antioxidant Effects of PPARα the ischemic retina

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 7, 2014, Pages 4568-4576

  Moran, Elizabeth ^a   Ding, Lexi ^a,b   Wang, Zhongxiao ^a   Cheng, Rui ^a   Chen, Qian ^a   Moore, Robert ^a   Takahashi, Yusuke ^a,c   Ma, Jian Xing ^a,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Apoptosis; Diabetic retinopathy; HIF 1; Hypoxia; Ischemia; Neurodegeneration; OIR

Indexed keywords

BETA ACTIN; CD31 ANTIGEN; DIMETHYL SULFOXIDE; FENOFIBRIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHOSGENE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE PROTECTION; GLIA CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NEWBORN; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; OXYGEN-INDUCED RETINOPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RETINA CELL; RETINA ISCHEMIA; WESTERN BLOTTING; WILD TYPE;

APOPTOSIS; DIABETIC RETINOPATHY; HIF-1; HYPOXIA; ISCHEMIA; NEURODEGENERATION; OIR;

ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FENOFIBRATE; HYPOLIPIDEMIC AGENTS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IN SITU NICK-END LABELING; ISCHEMIA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH OXIDASE; NERVE TISSUE PROTEINS; OXIDATIVE STRESS; OXYGEN; PPAR ALPHA; REACTIVE OXYGEN SPECIES; RETINAL DISEASES; RETINAL VESSELS;

EID: 84904823540     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13127     Document Type: Article

References (58)

1. Bordet R, Ouk T, Petrault O, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans. 2006;34:1341-1346.
2. Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol. 2010;6:454-463.
3. IJ A, Tan NS, Gelman L, et al. In vivo activation of PPAR target genes by RXR homodimers. EMBO J. 2004;23:2083-2091.
4. Hu YC, Chen Y, Ding L, et al. Pathogenic role of diabetesinduced PPAR-alpha down-regulation in microvascular dysfunction. Proc Natl Acad Sci U S A. 2013;110:15401-15406.
5. Sugden MC, Warlow MP, Holness MJ. The involvement of PPARs in the causes, consequences and mechanisms for correction of cardiac lipotoxicity and oxidative stress. Curr Mol Pharmacol. 2012;5:224-240.
6. Gervois P, Mansouri RM. PPARalpha as a therapeutic target in inflammation-associated diseases. Expert Opin Ther Targets. 2012;16:1113-1125.
7. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012;11:125.
8. Sehgal N, Kumawat KL, Basu A, Ravindranath V. Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection. PLoS One. 2012;7:e35427.
9. Bhateja DK, Dhull DK, Gill A, et al. Peroxisome proliferatoractivated receptor-alpha activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms. Eur J Pharmacol. 2012;674:33-43.
10. Mysiorek C, Culot M, Dehouck L, et al. Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivationinduced hyperpermeability in the blood-brain barrier. Curr Neurovasc Res. 2009;6:181-193.
11. Deplanque D, Gele P, Petrault O, et al. Peroxisome proliferatoractivated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003;23:6264-6271.
12. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571-580.
13. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687-1697.
14. Group AS, Group AES, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-244.
15. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227-1239.
16. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52:1156-1163.
17. Gastinger MJ, Singh RS, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci. 2006;47:3143-3150.
18. Zheng L, Gong B, Hatala DA, Kern TS. Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest Ophthalmol Vis Sci. 2007;48:361-367.
19. Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol. 2009;24:77-81.
20. Narayanan SP, Suwanpradid J, Saul A, et al. Arginase 2 deletion reduces neuro-glial injury and improves retinal function in a model of retinopathy of prematurity. PLoS One. 2011;6: e22460.
21. Mowat FM, Gonzalez F, Luhmann UF, et al. Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy. Am J Pathol. 2012;180:1726-1739.
22. Dorfman AL, Cuenca N, Pinilla I, Chemtob S, Lachapelle P. Immunohistochemical evidence of synaptic retraction, cytoarchitectural remodeling, and cell death in the inner retina of the rat model of oxygen-induced retinopathy (OIR). Invest Ophthalmol Vis Sci. 2011;52:1693-1708.
23. Li SY, Fu ZJ, Lo AC. Hypoxia-induced oxidative stress in ischemic retinopathy. Oxid Med Cell Longev. 2012;2012: 426769.
24. Kermorvant-Duchemin E, Sapieha P, Sirinyan M, et al. Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy. Doc Ophthalmol. 2010; 120:51-60.
25. Kleikers PW, Wingler K, Hermans JJ, et al. NADPH oxidases as a source of oxidative stress and molecular target in ischemia/ reperfusion injury. J Mol Med (Berl). 2012;90:1391-1406.
26. Kahles T, Brandes RP. NADPH oxidases as therapeutic targets in ischemic stroke. Cell Mol Life Sci. 2012;69:2345-2363.
27. Yokota H, Narayanan SP, Zhang W, et al. Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion. Invest Ophthalmol Vis Sci. 2011;52:8123-8131.
28. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes. 2010;59:1528-1538.
29. Spychalowicz A, Wilk G, Sliwa T, Ludew D, Guzik TJ. Novel therapeutic approaches in limiting oxidative stress and inflammation. Curr Pharm Biotechnol. 2012;13:2456-2466.
30. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE. 2007;2007:cm8.
31. Vadlapatla RK, Vadlapudi AD, Mitra AK. Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. Curr Drug Targets. 2013;14:919-935.
32. Diebold I, Petry A, Hess J, Gorlach A. The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol Biol Cell. 2010;21:2087-2096.
33. Lin M, Chen Y, Jin J, et al. Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells. Diabetologia. 2011;54:1554-1566.
34. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
35. Seigel GM. Review: R28 retinal precursor cells: the first 20 years. Mol Vis. 2014;20:301-306.
36. Moiseyev G, Chen Y, Takahashi Y, Wu BX, Ma JX. RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A. 2005;102:12413-12418.
37. Takahashi Y, Moiseyev G, Chen Y, Ma JX. Identification of conserved histidines and glutamic acid as key residues for isomerohydrolase activity of RPE65, an enzyme of the visual cycle in the retinal pigment epithelium. FEBS Letters. 2005; 579:5414-5418.
38. Zhang B, Ma JX. SERPINA3K prevents oxidative stress induced necrotic cell death by inhibiting calcium overload. PLoS One. 2008;3:e4077.
39. Lieth E, Gardner TW, Barber AJ, Antonetti DA; for the Penn State Retina Research Group. Retinal neurodegeneration: early pathology in diabetes. Clin Exp Ophthalmol. 2000;28:3-8.
40. Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy. Curr Diab Rep. 2011;11:253-264.
41. Imai H, Singh RS, Fort PE, Gardner TW. Neuroprotection for diabetic retinopathy. Dev Ophthalmol. 2009;44:56-68.
42. Chen Y, Hu Y, Lin M, et al. Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013;62:261-272.
43. Liu X, Zhang B, McBride JD, et al. Anti-angiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway. Diabetes. 2013;62:4228-4238.
44. Cherecheanu AP, Garhofer G, Schmidl D, Werkmeister R, Schmetterer L. Ocular perfusion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol. 2013;13:36-42.
45. McAllister IL. Central retinal vein occlusion: a review. Clin Exp Ophthalmol. 2012;40:48-58.
46. Zarbin MA. Age-related macular degeneration: review of pathogenesis. Eur J Ophthalmol. 1998;8:199-206.
47. Simo R, Hernandez C; for the European Consortium for the Early Treatment of Diabetic Retinopathy. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol. 2012;96:1285-1290.
48. Metea MR, Newman EA. Signalling within the neurovascular unit in the mammalian retina. Exp Physiol. 2007;92:635-640.
49. Riva CE, Logean E, Falsini B. Visually evoked hemodynamical response and assessment of neurovascular coupling in the optic nerve and retina. Prog Retin Eye Res. 2005;24:183-215.
50. Cervantes-Villagrana AR, Garcia-Roman J, Gonzalez-Espinosa C, Lamas M. Pharmacological inhibition of N-methyl d-aspartate receptor promotes secretion of vascular endothelial growth factor in Müller cells: effects of hyperglycemia and hypoxia. Curr Eye Res. 2010;35:733-741.
51. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord. 2008;9: 315-327.
52. Arden GB, Sivaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev. 2011;7: 291-304.
53. Krause KH, Lambeth D, Kronke M. NOX enzymes as drug targets. Cell Mol Life Sci. 2012;69:2279-2282.
54. Gao HM, Zhou H, Hong JS. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol Sci. 2012;33:295-303.
55. Radermacher KA, Wingler K, Langhauser F, et al. Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. Antioxid Redox Signal. 2013;18:1418-1427.
56. Kleinschnitz C, Grund H, Wingler K, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol. 2010;8.
57. Touyz RM, Briones AM, Sedeek M, Burger D, Montezano AC. NOX isoforms and reactive oxygen species in vascular health. Mol Interv. 2011;11:27-35.
58. Zhou J, Zhang S, Xue J, et al. Activation of peroxisome proliferator-activated receptor alpha (PPARalpha) suppresses hypoxia-inducible factor-1alpha (HIF-1alpha) signaling in cancer cells. J Biol Chem. 2012;287:35161-35169.